Clinical significance of β-catenin, hTERT, p53, and Wnt7A as biomarkers for ovarian cancer

Aim: The aim of the present study was to examine the association of β-catenin, hTERT, p53, and Wnt7A with the clinicopathologic features of epithelial ovarian carcinoma (EOC). Materials and Methods: By using qRT-PCR method, the authors attempted to elucidate the diagnostic evaluation of β-catenin, hTERT, p53, and Wnt7A mRNA for ovarian malignancy. Results: It was observed that, compared to the healthy control group, the expression levels of β-catenin, hTERT, p53, and Wnt7A were upregulated in all the ovarian cancer cases. The current study indicated that individual expression of β-catenin, hTERT and Wnt7A did not significantly correlate with patients’ clinicopathological parameters. However, expression of p53 significantly correlated with the FIGO Stage (p < 0.001) and histological grade (p < 0.001) of EOC patients. Conclusions: The mRNA expression levels of β-catenin, hTERT, p53, and Wnt7A were upregulated in all the ovarian cancer cases, compared to the healthy controls, which signifies their roles as ovarian cancer biomarkers. These biomarkers can be recognized as a potential important target for detection and anticancer therapies for ovarian cancer cases.

Wnt7A; p53; β-catenin; hTERT; Clinicopathological.

[1] T., Ogawa S., Kawano Y., Ohishi Y., Kobayashi H., Hirakawa T., Nakano H.: “Histological classification of ovarian cancer”. Med. Electron Microsc., 2003, 36, 9.

[2] Cadigan K.M., Nusse R.: “Wnt signaling: a common theme in animal development”. Genes Dev., 1997, 11, 3286.

[3] Angers S., Moon R.T.: “Proximal events in Wnt signal transduction”. Nat. Rev. Mol. Cell Biol., 2009, 10, 468.

[4] Polakis P.: “Wnt signaling and cancer”. Genes Dev., 2000, 14, 1837.

[5] Peifer M, Polakis P.: “Wnt signaling in oncogenesis and embryogenesis – a look outside the nucleus”. Science, 2000, 287, 1606.

[6] Hayashi K., Yoshioka S., Reardon S.N., Rucker E.B. III, Spencer T.E., Demayo F.J., et al.: “WNTs in the neonatal mouse uterus: potential regulation of endometrial gland development”. Biol. Reprod., 2011, 84, 308.

[7] Hayashi K., Burghardt R.C., Bazer F.W., Spencer T.E.: “WNTs in the ovine uterus: potential regulation of periimplantation ovine conceptus development”. Endocrinol., 2007, 148, 3496.

[8] Kolquist K.A., Ellisen L.W., Counter C.M., Meyerson M., Tan L.K., Weinberg R.A., et al.: Expression of TERT in early premalignant lesion and a subset of cells in normal tissues. Nat. Genet., 1998, 19, 182.

[9] Harley C.B., Futcher A.B., Greider C.W.: “Telomeres shorten during ageing of human fibroblasts”. Nature, 1990, 345, 458.

[10] Counter C.M., Hirte H.W., Bacchetti S., Harley C.B.: “Telomerase activity in human ovarian carcinoma”. Proc. Natl. Acad. Sci. USA, 1994, 9, 2900.

[11] Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W.: “Specific association of human telomerase activity with immortal cells and cancer”. Science, 1994, 266, 2011.

[12] Lamb P., Crawford L.: “Characterization of the human p53 gene”. Mol. Cell. Biol. 1986, 6, 1379.

[13] Corney D.C., Flesken-Nikitin A., Choi J., Nikitin A.Y.: “Role of p53 and Rb in Ovarian Cancer”. Adv. Exp. Med. Biol., 2008, 622, 99.

[14] Frum R.A., Grossman S.R.: “Mechanisms of mutant p53 stabilization in cancer”. Subcell. Biochem., 2014, 85, 187.

[15] Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C., Andersen T.I., Borresen A.L., Li F.P., Garber J.: “Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms”. N. Engl. J. Med., 1992, 326, 1309.

[16] Jin S., Levin A.J.: “The p53 functional circuit”. J. Cell Sci., 2001, 114, 4139.

[17] Liu W., Wu X., Zhang W., Montenegro R.C., Fackenthal D.L., Spitz J.A., et al.: “Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines”. Clin. Cancer Res., 2007, 13, 6788.

[18] Ji L., Cao X.F., Wang H.M., Li Y.S., Zhu B., Xiao J., Wang D.: “Expression level of beta-catenin is associated with prognosis of esophageal carcinoma”. World J. Gastroenterol., 2007, 13, 2622.

[19] Weglarz L., Molin I., Orchel A., Parfiniewicz B., Dzierzewicz Z.: “Quantitative analysis of the level of p53 and p21(WAF1) mRNA in human colon cancer HT-29 cells treated with inositol hexaphosphate”. Acta Biochim. Pol., 2006, 53, 349.

[20] Okoye U.C., Malbon C.C., Wang H.Y.: “Wnt and Frizzled RNA expression in human mesenchymal and embryonic (H7) stem cells”. J. Mol. Signal., 2008, 26, 3.

[21] Livak K.J., Schmittgen T.D.: “Analysis of relative gene expression data using real-time quantitative PCR and the 2–ΔΔCT Method”. Methods, 2001, 25, 402.

[22] Lengyel E.: “Ovarian cancer development and metastasis”. Am. J. Pathol., 2010, 177, 1053.

[23] Agarwal R., Kaye S.B.: “Ovarian cancer: strategies for overcoming resistance to chemotherapy”. Nat. Rev. Cancer, 2003, 3, 502.

[24] Sharma J.D., Kataki A.C., BarmanD., SharmaA., Kalita M.: “Cancer statistics in Kamrup urban district: Incidence and mortality in 2007–2011”. Indian J. Cancer, 2016, 53, 600.

[25] Lalwani N., Prasad S.R., Vikram R., Shanbhogue A.K., Huettner P.C., Fasih N.: “Histologic, Molecular, and Cytogenetic Features of Ovarian Cancers: Impli cations for Diagnosis and Treatment”. RadioGraphics, 2011, 31, 625.

[26] MacDonald B.T., Tamai K., He X.: “Wnt/beta-catenin signaling: components, mechanisms, and diseases”. Dev. Cell., 2009, 17, 9.

[27] Faleiro-Rodrigues C., Macedo-Pinto I., Pereira D., et al.: “Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas”. Hum. Pathol., 2004, 35, 663.

[28] Marques F.R., Fonsechi-Carvasan G.A., Angelo Andrade L.A., et al.: “Immunohistochemical patterns for alpha- and beta-catenin, E and N-cadherin expression in ovarian epithelial tumors”. Gynecol. Oncol., 2004, 94, 16.

[29] Moreno-Bueno G., Gamallo C., Perez-Gallego L., et al.: “Betacatenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas”. Diagn. Mol. Pathol. 2001, 10, 116.

[30] Saegusa M., Okayasu I.: “Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation”. J. Pathol., 2001, 194, 59.

[31] Zhai Y., Wu R., Schwartz D.R., Darrah D., Reed H., Kolligs F.T., et al.: “Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas”. Am. J. Pathol., 2002, 160, 1229.

[32] Zhang X.L., Peng C.J., Peng J., Jiang L.Y., Ning X.M., Zheng J.H.: “Prognostic role of Wnt7a expression in ovarian carcinoma patients”. Neoplasma, 2010, 57, 545.

[33] Yoshioka S., King M.L., Ran S., Okuda H., MacLean J.A., McAsey M.E., et al.: “Wnt7A regulates tumor growth and progression in ovarian cancer through the Wnt/A-catenin pathway”. Mol. Cancer Res., 2012, 10, 469.

[34] Psyrri A., Kountourakis P., Yu Z., Papadimitriou C., Markakis S., Camp R.L., et al.: “Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets”. Ann. Oncol. 2007, 18, 709–715.

[35] Kupryjanczyk J., Thor A.D., Beauchamp R., Merritt V., Edgerton S.M., Bell D.A., Yandell D.W.: “p53 gene mutations and protein accumulation in human ovarian cancer”. Proc. Natl. Acad. Sci. U S A, 1993, 90, 4961.

[36] Kupryjanczyk J., Bell D.A., Dimeo D., Beauchamp R., Thor A.D., Yandell D.W.: “p53 gene analysis of ovarian borderline tumors and stage I carcinomas”. Hum. Pathol. 1995, 26, 387.

[37] Zheng J., Benedict W.F., Xu H.J., Hu S.X., Kim T.M., Velicescu M., et al.: “Genetic disparity between morphologically benign cysts con-tiguous to ovarian carcinomas and solitary cystadenomas”. J. Natl. Cancer Inst., 1995, 87, 1146.

[38] Skomedal H., Kristensen G.B., Abeler V.M., Borresen-Dale A.L., Trope C., Holm R.: “TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas”. J. Pathol. 1997, 181, 158.

[39] O’Neill C.J., Deavers M.T., Malpica A., Foster H., McCluggage W.G.: “An immunohistochemical comparison between lowgrade and high-grade ovarian serous carcinomas: significantly higher ex-pression of p53, MIB1, BCL2, HER-2/neu, and C-KITin high-grade neoplasms”. Am. J. Surg. Pathol., 2005, 29, 1034.

[40] Pothuir B., Leitao M., Barakat R.,Akram M., Bogomolniy F., Olvera N., Lin O.: “Genetic analysis of ovarian carcinoma histogenesis”. Gynecol. Oncol., 2001, 80, 277.

[41] Werness B.A., Parvatiyar P., Ramus S.J.,Whittemore A.S., Garlinghouse-Jones K., Oakley-Girvan I., et al.: “Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53”. J. Natl. Cancer Inst., 2000, 92, 1088.

[42] Shih Ie M., Kurman R.J.: “Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis”. Am. J. Pathol., 2004, 164, 1511.

[43] McKenzie K.E., Umbricht C.B., Sukumar S.: “Applications of telomerase research in the fight against cancer”. Mol. Med. Today, 1999, 5, 114.

[44] Shay J.W., Bacchett S.: “A survey of telomerase activity in human cancer”. Eur. J. Cancer, 1997, 33, 787.

[45] Datar R.H., Naritoku W.Y., Li P., Tsao-Wei D., Groshen S., Taylor C.R., Imam S.A.: “Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas”. Gynecol. Oncol., 1999, 74, 338.

[46] Park T.W., Riethdorf S., Riethdorf L., Löning T., Jänicke F.: “Differenrial telomerase activity expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors”. Int. J. Cancer, 1999, 84, 426.

[47] Braunstein I., Cohen-Barak O., Shachaf C., Ravel Y., Yalon-Hacohen M., Mills G.B., et al.: “Human Telomerase Reverse Transcriptase Promoter Regulation in Normal and Malignant Human Ovarian Epithelial Cells”. Cancer Res., 2001, 61, 5529.

[48] Brustmann H.: “Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: A clinicopathologic study”. Gynecol. Oncol., 2005, 98, 396.

[49] Tantbirojn P., Triratanachat S., Trivijitsilp P., Niruthisard S.: “Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: An immunohistochemical study”. J. Med. Assoc. Thai., 2009, 92, 308.

[50] Hoos A., Hepp H.H., Kaul S., Ahlert T., Bastert G., Wallwiener D.: “Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer”. Int. J. Cancer, 1998, 79, 8.

[51] Nawaz S., Hashizumi T.L., Markham N.E., Shroyer A.L., Shroyer K.R.: “Telomerase expression in human breast cancer with and without lymph node metastases”. Am. J. Clin. Pathol. 1997, 107, 542